On May 22, 2020, Sinovac Biotech announced a transaction in which Advantech Capital and Vivo Capital have invested 15 million in Sinovac Research and Development, a wholly owned subsidiary of Sinovac, to further the development of an inactivated vaccine against COVID-19 named CoronaVac.